The Potential Dangers of Using MDMA for Psychotherapy
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
MDMA has properties that may make it attractive for psychotherapy, although many of its effects are potentially problematic. These contrasting effects will be critically reviewed in order to assess whether MDMA could be safe for clinical usage. Early studies from the 1980s noted that MDMA was an entactogen, engendering feelings of love and warmth. However, negative experiences can also occur with MDMA since it is not selective in the thoughts or emotions it releases. This unpredictability in the psychological material released is similar to another serotonergic drug, LSD. Acute MDMA has powerful neurohormonal effects, increasing cortisol, oxytocin, testosterone, and other hormone levels. The release of oxytocin may facilitate psychotherapy, whereas cortisol may increase stress and be counterproductive. MDMA administration is followed by a period of neurochemical recovery, when low serotonin levels are often accompanied by lethargy and depression. Regular usage can also lead to serotonergic neurotoxicity, memory problems, and other psychobiological problems. Proponents of MDMA-assisted therapy state that it should only be used for reactive disorders (such as PTSD) since it can exacerbate distress in those with a prior psychiatric history. Overall, many issues need to be considered when debating the relative benefits and dangers of using MDMA for psychotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”)
Green, A. R., Mechan, A. O., Elliott, J. M., O’Shea, E., & Colado, M. I. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.3.3 · Cited by 1,272
Vollenweider, F. X., Gamma, A., Liechti, M., & Huber, T. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00013-x · Cited by 448 · cited 1×
“It may also be noted that these drug-induced problems can be most pronounced in those with prior psychiatric susceptibilities (Caton et al. 2000; MacInnes et al. 2000; Parrott 2006; see also Dittrich 1994, cited in Vollenweider et al. 1998).”
BackgroundDoes cigarette smoking cause stress?
Parrott, A. C. (1999) · American Psychologist · doi:10.1037/0003-066x.54.10.817 · Cited by 447 · cited 1×
“Although many of these drugs do provide temporary relief, in the longer term, their repeated use tends to increase rather than reduce everyday stress (Parrott 1999; 2008).”
BackgroundSelf-citationSubjective Reports of the Effects of MDMA in a Clinical Setting
Greer, G., & Tolbert, R. (1986) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1986.10472364 · Cited by 413 · cited 13×
“Greer and Tolbert (1986) described two such cases.”
BackgroundInfluentialGender differences in the subjective effects of MDMA
Liechti, M. E., Gamma, A., & Vollenweider, F. X. (2001) · Psychopharmacology · doi:10.1007/s002130000648 · Cited by 360 · cited 4×
“Liechti et al. (2001) found some reports of feelings such as lack of energy, irritability, brooding, and bad dreams.”
BackgroundInfluential(±)3,4-Methylenedioxymethamphetamine (‘Ecstasy’)-Induced Serotonin Neurotoxicity: Clinical Studies
McCann, U. D., Eligulashvili, V., & Ricaurte, G. A. (2000) · Neuropsychobiology · doi:10.1159/000026665 · Cited by 190 · cited 2×
“Subsequent research has found that MDMA is associated with various deficits in memory and higher cognition (Curran & Travill 1997; Degenhardt & Hall 2009; Fox et al. 2001; 2002; Halpern et al. 2004; McCann et al. 2000; Parrott 2001; Parrott & Lasky 1998; Parrott et al. 2001; Parrott et al. 2004; Rodgers et al. 2003; 2…”
BackgroundA review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteers
Dumont, G. J. H., & Verkes, R. J. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106063271 · Cited by 149 · cited 2×
“Another safety issue is the effects of MDMA on the HPA axis, and the many somatic changes it causes (Dumont & Verkes 2006; Parrott 2009; 2013a).”
BackgroundParrott, A. C. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0703-5 · Cited by 87 · cited 3×
“Hence, there may be clinical reactions to this powerful and unpredictable drug (Greer & Tolbert 1986; Parrott 2007).”
BackgroundSelf-citationGreer, G. R., & Tolbert, R. (1990) · Topics in the Neurosciences · doi:10.1007/978-1-4613-1485-1_2 · Cited by 57 · cited 1×
“Greer and Tolbert (1986; 1990) suggested that one session with MDMA would be sufficient to engender enduring gains.”
Background
Cited by
Psychedelics and Psychedelic-Assisted Psychotherapy
Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodriguez, C. I., Kalin, N. H., McDonald, W. M., & and the Work Group on Biomarkers and Novel Treatments, A. D. O. T. A. P. A. C. O. R. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19010035 · Cited by 649
Reviewing the Potential of Psychedelics for the Treatment of PTSD
Krediet, E., Bostoen, T., Breeksema, J., van Schagen, A., Passie, T., & Vermetten, E. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa018 · Cited by 260
Acute subjective effects in LSD- and MDMA-assisted psychotherapy
Schmid, Y., Gasser, P., Oehen, P., & Liechti, M. E. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120959604 · Cited by 85
Positive psychology in the investigation of psychedelics and entactogens: a critical review
Jungaberle, H., Thal, S., Zeuch, A., Rougemont-Bücking, A., von Heyden, M., Aicher, H., & Scheidegger, M. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.06.034 · Cited by 70
Studies with psychedelic drugs in human volunteers
Sellers, E. M., Romach, M. K., & Leiderman, D. B. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.11.029 · Cited by 42
Metadata
- Authors
- Parrott, A. C.
- Venue
- Journal of Psychoactive Drugs
- Publisher
- Informa UK Limited
- Published
- 2014-01
- Volume
- 46
- Issue
- 1
- Pages
- 37-43
- ISSN
- 0279-1072 (ISSN-L)
- 2159-9777
- OpenAlex
- W2108846054
- Cited by
- 60
- References
- 9
- FWCI
- 11.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Potential Dangers of Using MDMA for Psychotherapy. https://app.cochat.ai/papers/10.1080/02791072.2014.873690
- The paper
- Parrott, A. C. (2014). The Potential Dangers of Using MDMA for Psychotherapy. Journal of Psychoactive Drugs. https://doi.org/10.1080/02791072.2014.873690
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.